BR112022018515A2 - Terapia de combinação para leucemia mieloide aguda - Google Patents
Terapia de combinação para leucemia mieloide agudaInfo
- Publication number
- BR112022018515A2 BR112022018515A2 BR112022018515A BR112022018515A BR112022018515A2 BR 112022018515 A2 BR112022018515 A2 BR 112022018515A2 BR 112022018515 A BR112022018515 A BR 112022018515A BR 112022018515 A BR112022018515 A BR 112022018515A BR 112022018515 A2 BR112022018515 A2 BR 112022018515A2
- Authority
- BR
- Brazil
- Prior art keywords
- combination therapy
- myeloid leukemia
- acute myeloid
- difluoroacetamide
- dioxopiperidin
- Prior art date
Links
- 208000031261 Acute myeloid leukaemia Diseases 0.000 title abstract 3
- 238000002648 combination therapy Methods 0.000 title abstract 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 title abstract 2
- PWBHUSLMHZLGRN-UHFFFAOYSA-N 2-(4-chlorophenyl)-N-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]methyl]-2,2-difluoroacetamide Chemical compound ClC1=CC=C(C=C1)C(C(=O)NCC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)(F)F PWBHUSLMHZLGRN-UHFFFAOYSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
TERAPIA DE COMBINAÇÃO PARA LEUCEMIA MIELOIDE AGUDA. A presente invenção refere-se a métodos de tratamento de LMA que compreendem a administração de 2-(4-clorofenil)-N-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida ou um estereoisômero ou mistura de estereoisômeros, sal farmaceuticamente aceitável, tautômero, profármaco, solvato, hidrato, cocristal, clatrato ou polimorfo da mesma em uma terapia de combinação.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062990372P | 2020-03-16 | 2020-03-16 | |
PCT/US2021/022182 WO2021188387A1 (en) | 2020-03-16 | 2021-03-12 | Combination therapy for acute myeloid leukemia |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022018515A2 true BR112022018515A2 (pt) | 2022-11-16 |
Family
ID=77772140
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022018515A BR112022018515A2 (pt) | 2020-03-16 | 2021-03-12 | Terapia de combinação para leucemia mieloide aguda |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230149379A1 (pt) |
EP (1) | EP4121051A4 (pt) |
JP (1) | JP2023520177A (pt) |
KR (1) | KR20220154175A (pt) |
CN (1) | CN115515582A (pt) |
AU (1) | AU2021239822A1 (pt) |
BR (1) | BR112022018515A2 (pt) |
CA (1) | CA3171588A1 (pt) |
IL (1) | IL296557A (pt) |
MX (1) | MX2022011523A (pt) |
WO (1) | WO2021188387A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4069228A4 (en) | 2019-12-06 | 2024-04-17 | Celgene Corp | PROCESS FOR PREPARING 2-(4-CHLORPHENYL)-N-((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-5-YL)METHYL)-2,2-DIFLUORACETAMIDE |
WO2023154904A2 (en) * | 2022-02-11 | 2023-08-17 | Loma Linda University | Compositions and methods for treating acute myeloid leukemia |
WO2024091959A1 (en) * | 2022-10-24 | 2024-05-02 | The Regents Of The University Of California | Drug resistant immune cells |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3399980A4 (en) * | 2016-01-08 | 2019-09-04 | Celgene Corporation | METHODS OF TREATING CANCER AND USE OF BIOMARKERS AS FACTORS PREDICTIVE OF CLINICAL SENSITIVITY TO TREATMENTS |
US10245258B2 (en) * | 2016-06-06 | 2019-04-02 | Celgene Corporation | Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
EP3644999B1 (en) * | 2017-06-30 | 2022-12-14 | Celgene Corporation | Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide |
-
2021
- 2021-03-12 BR BR112022018515A patent/BR112022018515A2/pt not_active Application Discontinuation
- 2021-03-12 IL IL296557A patent/IL296557A/en unknown
- 2021-03-12 MX MX2022011523A patent/MX2022011523A/es unknown
- 2021-03-12 AU AU2021239822A patent/AU2021239822A1/en active Pending
- 2021-03-12 JP JP2022556144A patent/JP2023520177A/ja active Pending
- 2021-03-12 CN CN202180033228.9A patent/CN115515582A/zh active Pending
- 2021-03-12 EP EP21772092.9A patent/EP4121051A4/en active Pending
- 2021-03-12 KR KR1020227035405A patent/KR20220154175A/ko unknown
- 2021-03-12 CA CA3171588A patent/CA3171588A1/en active Pending
- 2021-03-12 WO PCT/US2021/022182 patent/WO2021188387A1/en unknown
- 2021-03-12 US US17/912,001 patent/US20230149379A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4121051A1 (en) | 2023-01-25 |
CN115515582A (zh) | 2022-12-23 |
KR20220154175A (ko) | 2022-11-21 |
JP2023520177A (ja) | 2023-05-16 |
US20230149379A1 (en) | 2023-05-18 |
WO2021188387A1 (en) | 2021-09-23 |
CA3171588A1 (en) | 2021-09-23 |
AU2021239822A1 (en) | 2022-10-13 |
EP4121051A4 (en) | 2024-04-17 |
MX2022011523A (es) | 2022-12-13 |
IL296557A (en) | 2022-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022018515A2 (pt) | Terapia de combinação para leucemia mieloide aguda | |
BR112018075206A2 (pt) | tratamento de malignidade hematológica com 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida | |
MX2020005363A (es) | Compuestos heterociclicos como inhibidores de prmt5. | |
MY194405A (en) | Dihydropyrimidine compounds and uses thereof in medicine | |
ECSP18051143A (es) | Formulaciones de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida | |
AR061567A1 (es) | Compuestos puros enantiomericamente para el tratamiento de desordenes proliferativos | |
MX2022001784A (es) | Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos. | |
EA201590345A1 (ru) | Способы лечения рака с использованием 3-(4-((4-(морфолинометил)бензил)окси)-1-оксоизоиндолин-2-ил)пиперидин-2,6-диона | |
AR079208A2 (es) | Inhibidores de la actividad de proteina tirosina quinasa, composicion y uso de dichos inhibidores para la preparacion de un medicamento para tratar una enfermedad, trastorno o condicion oftalmica | |
MX2020013694A (es) | Compuestos heterocíclicos como inhibidores de trk. | |
MX2009001659A (es) | Compuestos de 2,5-dihidroxibenceno para el tratamiento de rosacea. | |
CO6361991A2 (es) | Compuestos enlazados con azufre para el tratamiento de enfermedades y trastornos oftalmicos. | |
MX2020001531A (es) | Nuevos compuestos hetorociclicos como inhibidores de cdk8/19. | |
BR112021006318A2 (pt) | terapia de combinação para o tratamento de câncer | |
MX2021007800A (es) | Composiciones y metodos para usar 2-(4-clorofenil)-n-((2-(2,6-diox opiperidin-3-il)-1-ox-oisoindolin-5il)metil)-2,2-difluoroacetamid a. | |
CO2022005861A2 (es) | Terapia de combinación con 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida | |
NZ778087A (en) | Pyrrolopyrimidine derivative and use thereof | |
CL2023000196A1 (es) | Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y métodos de uso de los mismos | |
CL2022002641A1 (es) | Agente para el tratamiento de lesión renal aguda inducida por medio de contraste | |
DOP2021000254A (es) | Compuestos de pirrolidina | |
MX2023003825A (es) | Derivados de tiadiazolona y su uso como agonistas de ampk para el tratamiento de la diabetes y trastornos relacionados. | |
BR112018074612A2 (pt) | forma cristalina de composto que suprimir a atividade de proteína quinase e aplicação da mesma | |
UY39799A (es) | Compuestos de pirrolil–sulfonamida | |
ECSP18023544A (es) | Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona | |
MX2022005199A (es) | Inhibidores de ssao y uso de los mismos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |